Endoscopic Sleeve Gastroplasty Yields 24% Total Body Weight Loss in Community Bariatric Practice
Patients undergoing ESG achieved 24% total body weight loss at 12 months in a bariatric surgery practice in a community setting.
Dr. Brandon VanderWel, Bariatric & Metabolic Surgeon at EVIVA in Seattle, Washington, presented the paper titled “Endoscopic Sleeve Gastroplasty Complements a Bariatric Surgery Practice.”[1]
This retrospective review measured the impact of integrating the ESG procedure into a bariatric surgery program, reporting both procedural volume and outcomes from 2020 to 2021.
Key Highlights:
- EVIVA received 469 new patient consults for ESG over a two-year period
- 197 patients (42%) underwent ESG; 107 patients (23%) received laparoscopic sleeve gastrectomy
- 24% total body weight loss and 75% excess body weight loss at 12 months
- 1% rate of serious adverse events
- In hypertensive patients (n=20): 45% remission, 20% improvement
- In diabetic patients (n=9): 55% remission, 33% improvement
“Millions of people are stuck in the disease of obesity but feel that surgery is too extreme for them. That is why we need more tools to fight obesity,” commented Dr. VanderWel. “Research confirms the ESG procedure is safe, effective, and a great complement to the field of bariatrics.”
“In addition to this Top 10 paper, endoscopic sleeve gastroplasty (ESG) and endoscopic bariatric revisions were included in more than 35 presentations and posters at IFSO 2022…” said Chas McKhann, President and CEO of Apollo.
